Beijing Tide Pharmaceutical Co., Ltd.
🇨🇳China
- Country
- 🇨🇳China
- Ownership
- Subsidiary
- Established
- 1995-05-29
- Employees
- -
- Market Cap
- -
- Website
- https://www.tidepharm.com
A Phase Ib/II Clinical Study in Patients With Refractory Chronic Cough
Phase 1
Not yet recruiting
- Conditions
- Refractory Chronic Cough
- Interventions
- Drug: TCR1672 tablet
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-01-19
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT06213363
TDI01 Suspension in the Treatment of Chronic Graft-versus-host Disease (cGVHD))
Phase 1
Recruiting
- Conditions
- GVHD, Chronic
- Interventions
- Drug: TDI01 suspension
- First Posted Date
- 2023-12-13
- Last Posted Date
- 2024-08-13
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06169722
- Locations
- 🇨🇳
Peking University People's Hospital, Beijing, Beijing, China
A Clinical Trial on the Treatment of Idiopathic Pulmonary Fibrosis
Phase 2
Not yet recruiting
- Conditions
- Idiopathic Pulmonary Fibrosis
- Interventions
- Drug: TDI01 suspension
- First Posted Date
- 2023-10-26
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT06102083
A Phase I/II Clinical Study in Patients with Advanced Solid Tumor.
Phase 1
Recruiting
- Conditions
- Patients with Advanced Solid Tumors
- Interventions
- Drug: TCC1727 tablet（1）Drug: TCC1727 tablet（2）
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2025-03-21
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 56
- Registration Number
- NCT05970016
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Efficacy, Safety and Tolerability Study of Meloxicam Injection in Subjects After Abdominal Surgery
Phase 2
Not yet recruiting
- Conditions
- Pain, Post-operative
- Interventions
- First Posted Date
- 2023-07-18
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 108
- Registration Number
- NCT05950152
- Locations
- 🇨🇳
the Third XiangYa Medical Hospital of Central South University, Changsha, Hunan, China
Efficacy and Safety Evaluation of PC-SOD for Injection in Reducing Myocardial Reperfusion Injury
- First Posted Date
- 2019-06-24
- Last Posted Date
- 2019-09-26
- Lead Sponsor
- Beijing Tide Pharmaceutical Co., Ltd
- Target Recruit Count
- 120
- Registration Number
- NCT03995732
- Locations
- 🇨🇳
Wuhan Asia Heart Hospital, Wuhan, Hubei, China
🇨🇳Zhongshan Hospital, Shanghai, Shanghai, China
© Copyright 2025. All Rights Reserved by MedPath